AFP and neoplasm: In addition, of patients who showed a discordant tumor marker response (A↓P↑ or A↑P↓), those of the A↑P↓ group who were AFP nonresponders had better progression-free and overall survival than did A↓P↑ patients (10.1 versus 5.1 months, P = 0.038; 22.4 versus 7.3 months, P = 0.038, resp).